U
NNVC icon

UBS’s NanoViricides NNVC Stock Holding History

UBS’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-65
Closed -$6K – 10609
2014
Q2 		$6K Buy
+65
New +$4.61K ﹤0.01% 9351

Other funds holding NNVC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UBS's NNVC Position: Q3 2014 in Review

UBS increased its NanoViricides (NNVC) stake by 88% in Q3 2014, buying an estimated $78.9K and bringing the position to 2,141 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #5686.

UBS first reported a position in NNVC in Q4 2013 and has held it in 4 quarters since. The position peaked at $459K in Q1 2014. 53 funds tracked by Wall St. Rank hold NNVC as of Q3 2014.

  • UBS held 2,141 shares of NanoViricides worth $128K as of Q3 2014.
  • UBS bought 1,005 NanoViricides shares in Q3 2014, an estimated $78.9K.
  • NanoViricides made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5686 holding.
  • UBS first reported a position in NanoViricides in Q4 2013 and has held it in 4 quarters since.
  • UBS's NanoViricides position peaked at $459K in Q1 2014.
  • 53 funds tracked by Wall St. Rank held NanoViricides as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.